Postmastectomy radiotherapy for all node positive patients: The case against

Area of Science:

• Oncology
• Radiotherapy
• Breast Cancer Research

Background:

• Postmastectomy radiotherapy (PMRT) is standard for early breast cancer with >=4 positive axillary nodes.
• The necessity of PMRT for patients with 1-3 positive axillary nodes remains a subject of ongoing debate and varied clinical guidelines.
• Current evidence does not uniformly support the routine use of PMRT in all node-positive breast cancer cases.

Purpose of the Study:

• To critically evaluate and present arguments against the universal recommendation of postmastectomy radiotherapy for all women diagnosed with node-positive breast cancer.
• To address the controversy surrounding the application of PMRT in early breast cancer patients with limited axillary node involvement (1-3 nodes).

Main Methods:

• Review of existing clinical guidelines and relevant scientific literature.
• Analysis of the evidence supporting and refuting the use of PMRT in node-positive breast cancer.
• Synthesis of arguments to challenge the routine application of PMRT in specific patient subgroups.

Main Results:

• The role of PMRT in early breast cancer with 1-3 positive axillary nodes is not definitively established.
• Existing guidelines present inconsistencies regarding the recommendation of PMRT for patients with limited nodal disease.
• Evidence supporting the benefit of PMRT in all node-positive cases is inconclusive, particularly for those with fewer than 4 positive nodes.

Conclusions:

• The routine use of postmastectomy radiotherapy for all node-positive breast cancer patients, especially those with 1-3 involved nodes, should be reconsidered.
• Clinical decision-making regarding PMRT should be individualized based on a thorough assessment of risks and benefits.
• Further research is warranted to clarify the precise indications for PMRT in early breast cancer with limited nodal metastasis.